Stages of a Transtheoretical Model as Predictors of the Decline in Estimated Glomerular Filtration Rate: A Retrospective Cohort Study

Daisuke Takada1, Susumu Kunisawa1, Akira Kikuno2, Tomoko Iritani2, and Yuichi Imanaka1

1Department of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Kyoto, Japan
2Japan Health Insurance Association Kyoto, Kyoto, Japan

Received August 28, 2020; accepted January 11, 2021; released online January 23, 2021

ABSTRACT

Background: The transtheoretical model (TTM) is composed of the multiple stages according to patient’s consciousness and is believed to lead people to realize the importance of healthier behaviors. We examined the association of TTM stages with the decline of estimated glomerular filtration rate (eGFR).

Methods: We used the annual health checkup data and health insurance claims data of the Japan Health Insurance Association in Kyoto Prefecture between April 2012 and March 2016. TTM stages of change obtained from questionnaires at the first health checkup and categorized into six groups. The primary outcome was defined as a more than 30% decline in eGFR from the first health checkup. We fitted multivariable Cox proportional-hazards model for time-to-event analyses adjusting for age, sex, eGFR, body mass index, blood pressure, blood sugar, dyslipidemia, uric acid, urinary protein, and existence of kidney diseases at first health checkup.

Results: We analyzed 239,755 employees and the mean follow-up was 2.9 (standard deviation, 1.2) years. As compared with the stage 1 group, the risk of eGFR decline was significantly low in the stage 3 group (hazard ratio [HR] 0.77; 95% confidence interval [CI], 0.65–0.91); stage 4 group (HR 0.80; 95% CI, 0.65–0.98); and stage 5 group (HR 0.79; 95% CI, 0.66–0.95).

Conclusion: Compared with the precontemplation stage (stage 1), the preparation, action and maintenance stages (stages 3, 4, and 5), were associated with a lower risk of eGFR decline.

Key words: transtheoretical model; chronic kidney disease; kidney injury; stage of change; more than 30% decline in estimated glomerular filtration rate

INTRODUCTION

Chronic kidney disease (CKD) has been a global health problem for many years, and its prevalence has reached approximately 10–15% worldwide among 500 million people.1 CKD progression is caused by many pathophysiological risks such as diabetes, hypertension, and systemic immune disorders.1 Recently, dietary and lifestyle modifications were found to affect renal function, so the Kidney Disease: Improving Global Outcomes (KDIGO) guideline now recommends that CKD patients should monitor and change their behaviors, including smoking cigarettes, their healthy weights, and daily physical activity.2 In fact, the evidence that being a past smoker compared with current smoker was associated with a decreased risk of CKD progression3 indicates that behavior change might slow the disease progression. However, an issue would be that changing such healthy behaviors does not seem easy in clinical settings. Recently, some integrative theories of psychotherapies have evolved to address this issue.

The transtheoretical model (TTM) of behavior change is one of the integrative theories that divide common people into five categories based on temporal dimensions.4 In general, people move through five stages from precontemplation to contemplation, and then preparation, followed by action and maintenance stages when they change their behavior. Recent studies have documented that TTM-based intervention improved adherence with lipid-lowering or antihypertensive drugs,5–6 and promoted healthy eating, exercise, and other healthy behaviors in a randomized controlled trial.7

Nevertheless, it is important to understand the precise mechanisms by which behaviors affect renal function. The first step would be to determine whether each stage is associated with CKD progression. Here, we examined whether CKD progression is associated with TTM stages using the health-checkup Japanese database.

METHODS

Database and target populations
We performed a retrospective analysis using annual health checkup data and health insurance claims data of employers in companies insured in the Japan Health Insurance Association in
Kyoto prefecture, Japan. Annual health checkups of employees aged more than 35 years are mandatory until they lose their eligibility (eg, quittance/change jobs, moving to other area, or death).

**Inclusion and exclusion criteria of participants**
We recruited employees who were between 35 and 75 years old and had two or more health checkups from April 2012 to March 2016. We excluded those who had any kidney disease or missing data in the first health checkup. Questionnaires were acquired in each health checkup and contained the information on prescribed drugs, healthy behaviors, and alcohol consumption. Kidney disease was defined by the International Classification of Diseases, 10th Revision codes, such as N00-08, I70, and Q61, in the claims data.

**Baseline variables**
TTM stages of a change obtained from questionnaires at the baseline variables data in the first health checkup. Questionnaires were acquired in each health checkup and contained the information on prescribed drugs, healthy behaviors, and alcohol consumption. Kidney disease was defined by the International Classification of Diseases, 10th Revision codes, such as N00-08, I70, and Q61, in the claims data.

**Statistical analysis**
The primary outcome for survival analysis was defined as a decrease of 30% or more in eGFR. The eGFR was calculated by the equation used by the Japanese Society of Nephrology. Patients were followed until the outcome or censored.

The Cox proportional-hazards model was used for time-to-event analyses to estimate the hazard ratios (HRs); 95% confidence interval (CI) were used for the primary outcome. Follow-up period data for patients were censored on the date of the last health checkup. The analysis used two types of models: model 1 (without medication factors), adjusted for age, sex, BMI, abdominal circumference, eGFR, and urinary protein; and model 2 (with medication factors), adjusted for age, sex, BMI, abdominal circumference, eGFR, urinary protein, blood pressure, blood sugar, dyslipidemia, and uric acid. All the covariates were detected at the first health checkup. Schoenfeld residuals were used to check the proportional hazards assumption. A two-sided significance level of 0.05 was used, and all analyses were conducted using R version 3.4.1 (R Foundation for Statistical Computing, Vienna, Austria).

Subgroup analyses were performed for the model 2 condition, where the analysis population was stratified by employees 1) whose eGFR categorized as >60, 60–45, or ≤45 mL/min/1.73 m² and 2) who did not attend hospital because of diabetes (no medication to reduce blood sugar or insulin injection), and 3) who met 1 or more criteria for Japanese metabolic syndrome.

Sensitivity analyses were also performed for the model 2 condition, where we excluded from the analysis population 1) employees aged 60 or more years or 2) employees who had taken any medication for hypertension, diabetes, or dyslipidemia. The former employees were excluded because retirement is more likely to occur 60–65 years in Japan, which may cause healthy workers bias, and we minimized the impact of employees lost to follow-up.

**RESULTS**
A total of 253,673 employees were enrolled and fulfilled the inclusion criteria; 12,593 (4.9%) were excluded due to missing data and 1,392 due to the prevalence of kidney disease. We analyzed the remaining 239,755 employees (Figure 1). By the end of follow-up, there were 1,839 persons (0.8%) whose eGFR decreased 30% or more, and the mean follow-up was 2.9 (standard deviation, 1.2) years.

The characteristics of each stage are shown in Table 1. The group of stage 5 tended to have a higher serum creatinine and eGFR, indicating that the group is more likely to be affected by kidney disease.
higher proportion of prescription drugs, including for diabetes and dyslipidemia. The proportion of physical activity changes at 1 year after the first health check-up tended to be higher in stages 3–5 than in stages 1–2. In particular, the proportion of undertaking physical activity was 8.0% in stage 3; 12.0% in stage 4; and 8.6% in stage 5, compared with 5.3% in stage 1; 5.2% in stage 2.

Compared with the stage 1 group, the risk of decreasing renal function was significantly lower in the stage 3 group (HR 0.77; 95% CI, 0.65–0.91); in the stage 4 group (HR 0.80; 95% CI, 0.66–0.95), after adjusting for age, sex, eGFR, body mass index, blood pressure, blood sugar, dyslipidemia, uric acid, urinary protein (Table 2). The forests plots of the HRs of other covariates are shown in Figure 2, which shows that urinary protein, diabetes, blood pressure, age, and lower eGFR were associated with decreasing renal function.

The major results of the subgroup analysis are shown in Figure 3. When we included 226,667 employees whose eGFR was >60 mL/min/1.73 m², the hazard ratios of decreasing renal function were 0.95 (95% CI, 0.83–1.09) in the stage 2 group, 0.76 (95% CI, 0.63–0.92) in the stage 3 group, 0.83 (95% CI, 0.67–1.04) in the stage 4 group, and 0.84 (95% CI, 0.69–1.03) in the stage 5 group, compared with the stage 1 group. When we included 12,049 employees whose eGFR was 45–60 mL/min/1.73 m², the hazard ratios of decreasing renal function were 0.78 (95% CI, 0.49–1.26) in the stage 2 group, 0.81 (95% CI, 0.45–1.48) in the stage 3 group, 0.19 (95% CI, 0.06–0.61) in the stage 4 group, and 0.65 (95% CI, 0.34–1.22) in the stage 5 group, compared with the stage 1 group. When we included 1,039 employees whose eGFR was ≤45 mL/min/1.73 m², the hazard ratios of decreasing renal function were 0.98 (95% CI, 0.60–1.58) in the stage 2 group, 0.87 (95% CI, 0.50–1.52) in the stage 3 group, 1.19 (95% CI, 0.63–2.23) in the stage 4 group, and 0.70 (95% CI, 0.40–1.23) in the stage 5 group, compared with the stage 1 group. The trend of point estimates did not change fundamentally in other subgroups.

The sensitivity analysis also showed similar hazard ratios. When we excluded employees aged 60 or more years, the results were 0.95 (95% CI, 0.82–1.09) in the stage 2 group, 0.77 (95% CI, 0.63–0.94) in the stage 3 group, 0.83 (95% CI, 0.65–1.05) in the stage 4 group, 0.75 (95% CI, 0.60–0.95) in the stage 5 group, and 0.99 (95% CI, 0.84–1.18) for the unknown stage group, compared with the stage 1 group. When we excluded employees who had taken any medication for hypertension, diabetes, or dyslipidemia, the results were 1.07 (95% CI, 0.91–1.25) in the stage 2 group, 0.79 (95% CI, 0.63–1.00) in the stage 3 group, 0.68 (95% CI, 0.50–0.93) in the stage 4 group, 0.75 (95% CI, 0.56–0.99) in the stage 5 group, and 1.14 (95% CI, 0.94–1.37) in the unknown stage group, compared with the stage 1 group.

**DISCUSSION**

We found that persons in stages 3–5 had a habit of healthier behaviors with a lower risk of eGFR decline after adjusting for confounding factors, compared with those who were in stage 1. In particular, those who were in stage 3 (preparation stage) showed less eGFR decline than those in stages 4 or 5 (action, maintenance stage), whereas those in stage 4 or 5 had a slightly higher risk of eGFR decline than those in stage 3.

TTM is a therapeutic theory that led people to realize the importance of healthier behaviors according to their consciousness of the behaviors.4 In several studies, TTM theory has been applied to subjects with lifestyle diseases and improved their behaviors on weight management, adherence to antihypertensive medication, and adherence to lipid-lowering drugs.5–7

The present study, with 1-year follow-up questionnaires, is shown in Table 1. It demonstrated that those in stages 3–5, but not in stages 1–2, improved their various kinds of behaviors. Although our study targeted the general population, similar findings were observed in CKD patients. In fact, a systematic review revealed that undertaking physical activity is correlated with mortality rates and the reduction of adverse clinical events in CKD patients,12 suggesting that such healthy behaviors contribute
Table 1. Summary of patient characteristics for each stage of change according to the transtheoretical model

| Chronic Kidney Disease Stage, n (%) | Stage 1: Precontemplation (not ready) | Stage 2: Contemplation (getting ready) | Stage 3: Preparation (ready) | Stage 4: Action (current action) | Stage 5: Maintenance (monitoring) | Unknown: No concern |
|------------------------------------|----------------------------------------|----------------------------------------|----------------------------|--------------------------------|---------------------------------|--------------------|
| Total number                        | 60,535                                 | 80,522                                 | 27,285                     | 16,110                         | 19,889                          | 35,414             |
| Sex, male (%)                       | 41,935 (69.3%)                        | 51,407 (63.8%)                        | 17,363 (63.6%)             | 10,433 (64.8%)                 | 14,079 (70.8%)                 | 23,671 (66.8%)     |
| Age, mean (SD)                      | 48.6 (10.0)                            | 47.1 (9.4)                             | 47.3 (9.4)                 | 47.7 (9.7)                     | 51.1 (10.0)                    | 48.1 (9.5)         |
| Serum creatinine, mean (SD) µmol/L | 0.76 (0.20)                            | 0.75 (0.19)                            | 0.77 (0.24)                | 0.78 (0.23)                    | 0.80 (0.31)                    | 0.77 (0.26)        |
| estimated glomerular filtration rate, mean (SD) mL/min/1.73 m² | 81.8 (14.8)                            | 82.1 (14.6)                            | 80.9 (14.6)                | 79.8 (14.6)                    | 77.8 (14.6)                   | 81.1 (14.6)        |
| Abdominal circumference, male       |                                        |                                        |                            |                                |                                |                    |
| Urinary protein, n (%)              |                                        |                                        |                            |                                |                                |                    |
| Diabetes,a n (%)                    |                                        |                                        |                            |                                |                                |                    |
| high, no drugs                      | 4,930 (8.1%)                          | 7,330 (9.1%)                           | 2,677 (9.8%)               | 1,438 (8.9%)                   | 1,989 (10.0%)                  | 3,375 (9.6%)        |
| normal with drugs                   | 144 (0.2%)                            | 273 (0.3%)                             | 109 (0.4%)                 | 118 (0.73%)                    | 235 (1.2%)                     | 228 (0.6%)         |
| high with drugs                     | 882 (1.5%)                            | 1,681 (2.1%)                           | 775 (2.8%)                 | 621 (3.9%)                     | 1,189 (6.0%)                   | 3,375 (9.6%)        |
| Dyslipidemia,b n (%)                |                                        |                                        |                            |                                |                                |                    |
| high, no drugs                      | 10,000 (16.5%)                        | 16,585 (26.0%)                         | 6,027 (22.1%)              | 3,275 (20.3%)                  | 3,286 (16.5%)                  | 6,866 (19.4%)       |
| normal with drugs                   | 1,742 (2.9%)                          | 2,937 (3.6%)                           | 1,414 (4.2%)               | 869 (5.4%)                     | 1,481 (7.4%)                   | 1,478 (4.2%)        |
| high with drugs                     | 701 (1.2%)                            | 1,541 (1.9%)                           | 620 (2.3%)                 | 439 (2.7%)                     | 579 (2.9%)                     | 728 (2.1%)          |
| High uric acid or prescribed antihyperuricemic drugs, n (%) | 2,096 (3.5%)                          | 3,456 (4.3%)                           | 1,267 (4.6%)               | 780 (4.9%)                     | 773 (3.9%)                     | 1,400 (4.0%)        |
| The improvement of healthy behaviors after 1 yearc | 1,286 (2.1%)                          | 1,849 (2.3%)                           | 646 (2.4%)                 | 370 (2.3%)                     | 326 (1.6%)                     | 518 (1.5%)          |
| Quitting smoking                    | 3,236 (5.3%)                          | 4,176 (5.2%)                           | 2,189 (8.0%)               | 1,930 (12.0%)                  | 1,707 (8.6%)                   | 291 (0.8%)          |
| Undertaking physical activity       | 5,818 (9.6%)                          | 7,943 (9.9%)                           | 2,861 (10.5%)              | 1,630 (10.1%)                  | 1,940 (9.8%)                   | 207 (0.6%)          |
| Decrease in the amount of drinking  | 3,967 (6.6%)                          | 5,791 (7.2%)                           | 2,110 (7.7%)               | 1,185 (7.4%)                   | 1,404 (7.1%)                   | 372 (1.1%)          |
| Decrease in the frequency of drinking | 5,818 (9.6%)                          | 7,943 (9.9%)                           | 2,861 (10.5%)              | 1,630 (10.1%)                  | 1,940 (9.8%)                   | 207 (0.6%)          |
| Change to normal weight             | 2,250 (3.7%)                          | 3,056 (3.8%)                           | 1,070 (3.9%)               | 616 (3.8%)                     | 634 (3.2%)                     | 372 (1.1%)          |
| (body mass index greater than or equal to 18.5 to 24.9 kg/m²) |                                        |                                        |                            |                                |                                |                    |
| SD, standard deviation.             |                                        |                                        |                            |                                |                                |                    |
| aDiabetes “high”: fasting blood sugar ≥110 mg/dL or hemoglobin A1c ≥5.6%.  
| bDyslipidemia “high”: triglyceride ≥150 mg/dL or high-density lipoprotein cholesterol <40 mg/dL.  
| cEven though the questionnaire in the next year contained missing values, we did not remove it from the denominator. |

Table 2. Cox proportional hazards regression models showing the effects on the risk of estimated glomerular filtration rate decline

| Number of outcomes | Incident rate per 1,000 person-years (95% CI) | Hazard ratios in model 1* | Hazard ratios in model 2* |
|--------------------|-----------------------------------------------|---------------------------|--------------------------|
| Stage 1: Precontemplation (not ready) | 461/60,535 | 0.73 (0.68-0.78) | reference |
| Stage 2: Contemplation (getting ready) | 608/80,522 | 0.76 (0.62-0.70) | 0.97 (0.86-1.10) | 0.80 (0.65-0.89) |
| Stage 3: Preparation (ready) | 190/27,285 | 0.65 (0.62-0.68) | 0.82 (0.69-0.97) | 0.77 (0.65-0.91) |
| Stage 4: Action (current action) | 117/16,110 | 0.60 (0.55-0.66) | 0.83 (0.67-1.02) | 0.80 (0.65-0.98) |
| Stage 5: Maintenance (monitoring) | 161/19,889 | 0.61 (0.54-0.68) | 0.87 (0.72-1.04) | 0.79 (0.66-0.95) |
| Unknown: No concern | 299/35,414 | 0.70 (0.63-0.77) | 1.04 (0.90-1.20) | 0.98 (0.85-1.13) |

CL confidence interval. Model 1: adjusted for age, sex, body mass index, estimated glomerular filtration rate at baseline, and urinary protein. (without medication factors). Model 2: adjusted for model 1 plus blood pressure, blood sugar, dyslipidemia, and uric acid. (with medication factors).

SD, standard deviation.  
*Diabetes “high”: fasting blood sugar ≥110 mg/dL or hemoglobin A1c ≥5.6%.  
**Dyslipidemia “high”: triglyceride ≥150 mg/dL or high-density lipoprotein cholesterol <40 mg/dL.  
†Even though the questionnaire in the next year contained missing values, we did not remove it from the denominator.

to slowing eGFR decline in stages 3–5. Currently, the KDIGO guideline recommends that CKD patients undertake more physical activities.

Whereas those in stages 3–5 were associated with a lower decline of renal function, those in stage 3 had better prognosis than stages 4–5. The difference could be explained by the status of physical activity and diet. According to Prochaska, the stage 3 is defined as “the stage in which people are intending to take action in the immediate future, usually measured as the next month”. This means that employees in stage 3 do not conduct physical activities.
actions and diets but intend to improve their behavior. Therefore, improvement of their behavior would be achieved and lead to a beneficial outcome. In contrast, those in stages 4–5 are subjects who have already made significant modifications to their lifestyle such that they have little room to further improve their behaviors.

The benefit of TTM-based intervention for improving health outcomes remains controversial. In fact, some researchers often failed to show a positive effect. As a result, a Cochrane systematic review could not conclude that TTM-based intervention might be effective in weight loss. This discrepancy could be accounted for in part by the distinct target stages. A TTM-based method may lead us to classify target stages of TTM in which patients’ health conditions could improve effectively in terms of the results of laboratory tests, such that we can promote patients’ awareness of healthy behaviors to elevate their TTM-stages. In our case, an analysis was performed for subjects in each stage. As a result, we found positive results only in stages 3–5, suggesting that the effect might vary between each stage. Therefore, when all stages were combined in other reports, a positive effect in any specific stage may have been canceled out by no effect in other stages. Consistently, a previous randomized trial showed that HbA1c was significantly reduced in diabetic patients in pre-action stages, whereas such an effect was canceled when subjects in all stages were analyzed together. Our results would imply that targeting specific stages would improve the results of laboratory tests effectively.

The next issue is how to move patients from stages 1–2 to stages 3–5 in clinical settings. In this regard, Prochaska et al developed a TTM-based intervention aiming to lead patients to move onto different stages. They showed that four processes are important to change stages: “Consciousness raising”, getting the facts; “Dramatic relief”, paying attention to feelings; “Environmental reevaluation”, noticing your effect on others; and “Self-liberation”, making a commitment. Perhaps, it may be of importance for us to educate patients to understand what healthy behaviors are, how to change and consolidate their behaviors, and what they can do for the health of those around them. These processes could proceed to a change of healthy behaviors to reduce kidney injury.

In addition to improving the healthy behaviors, maintaining the habit is another critical issue in traditional cognitive behavior therapies. Cooper et al examined the effect of cognitive behavioral treatment on body weight in obese people. It was
found that the effect of behavioral therapy was transient, and the great majority regained almost all the weight that they had lost with behavioral treatment during the 3 years in the randomized controlled trial, indicating that maintaining healthy behaviors would be difficult. Alternatively, several researchers have indicated that the new cognitive therapies, including acceptance-based behavioral treatment or mindful intervention, might be an option to improve the maintenance of healthy behaviors. Future studies might discover more effective methods of intervention.

There were several limitations to our study. First, we dealt with all the competing events, including acute kidney injury (AKI), as censored events, and it might cause healthy worker bias. However, AKI might occur regardless of the stages of behavioral change, AKI incidence is reported at a low rate of 500 persons per 1,000,000, and all-cause mortality in patients with AKI is estimated as one in four or less. Second, our study did not consider several unmeasured confounding factors, including dietary or exercise habits. Further studies, including a causal mediation analysis, are needed to confirm the impact of such lifestyle habits, even though it is difficult to quantify them accurately.

Conclusion
Compared with the precontemplation stage (stage 1), the preparation, action, and maintenance stages (stages 3, 4, and 5), were associated with healthier behavior and a lower risk of eGFR decline after adjusting for confounding factors. The effect of TTM-based therapy may be clarified further in a specific population that performs healthy behaviors.

ACKNOWLEDGEMENTS
We acknowledge all the participants.

Ethical considerations: The study protocol was approved by the ethics committee of Kyoto University Graduate School and the Faculty of Medicine (approval number: R1631) and approved by the ethics committee of Japan Health Insurance Association. The participants were informed to join statistical surveys and researches, which handle personal information in a form making it hard to identify, in records. The data underlying this article cannot be shared publicly due to the Japanese law: “Act on the Protection of Personal Information”. The data will be shared on reasonable request to the corresponding author.

Conflicts of interest: None declared.

Authors’ contributions: AK, TI, DT performed statistical analysis and had full access to all of the data in this study. SK, YI contributed to the design and conduct of the study. YI is the principal investigator of the study. All authors approved the final manuscript version to be published and agreed to be accountable.
for all aspects of the work. Each author contributed important intellectual content during manuscript drafting or revision, accepts personal accountability for the author’s own contributions, and agrees to ensure that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

Funding source: The publication charges for this article were funded from a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (16H02634, 19H01075). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

REFERENCES

1. Levin A, Tonelli M, Bonventre J, et al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet. 2017;390:1888–1917.
2. Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63:713–735.
3. Oyeyomi SO, Braaten T, Skeie G, Borch KB. Competing mortality risks analysis of prediagnostic lifestyle and dietary factors in colorectal cancer survival: the Norwegian Women and Cancer Study. BMJ Open Gastroenterol. 2019;6:e000338.
4. Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am J Health Promot. 1997;12:38–48.
5. Johnson SS, Driskell MM, Johnson JL, et al. Transtheoretical model intervention for adherence to lipid-lowering drugs. Dis Manag. 2006;9:102–114.
6. Johnson SS, Driskell MM, Johnson JL, Prochaska JM, Zwick W, Prochaska JO. Efficacy of a transtheoretical model-based expert system for antihypertensive adherence. Dis Manag. 2006;9:291–301.
7. Johnson SS, Paiva AL, Cummins CO, et al. Transtheoretical model-based multiple behavior intervention for weight management: effectiveness on a population basis. Prev Med. 2008;46:238–246.
8. Japanese Ministry of Health Law. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000194155.html Accessed 04.01.20.
9. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–992.
10. Kanda E, Usui T, Kashiwara N, Iseki C, Iseki K, Nagakuki M. Importance of glomerular filtration rate change as surrogate endpoint for the future incidence of end-stage renal disease in general Japanese population: community-based cohort study. Clin Exp Nephrol. 2018;22(2):318–327.
11. Yamagishi K, Iso H. The criteria for metabolic syndrome and the national health screening and education system in Japan. Epidemiol Health. 2017;39:e2017003.
12. MacKinnon HJ, Wilkinson TJ, Clarke AL, et al. The association of physical function and physical activity with all-cause mortality and adverse clinical outcomes in nondialysis chronic kidney disease: a systematic review. Ther Adv Chronic Dis. 2018;9:209–226.
13. Logue E, Sutton K, Jarjoura D, Smucker W, Baughman K, Capers C. Transtheoretical model-chronic disease care for obesity in primary care: a randomized trial. Obes Res. 2005;13:917–927.
14. Bridle C, Riemsma RP, Pattenden J, et al. Systematic review of the effectiveness of behavior health interventions based on the transtheoretical model. Psychol Health. 2005;20:283–301.
15. Mastellos N, Gunn LH, Felix LM, Car J, Majeed A. Transtheoretical model stages of change for dietary and physical exercise modification in weight loss management for overweight and obese adults. Cochrane Database Syst Rev. 2014;CD008066.
16. Jones H, Edwards L, Vallis TM, et al. Changes in diabetes self-care behaviors make a difference in glycemic control: the Diabetes Stages of Change (DiSC) study. Diabetes Care. 2003;26:732–737.
17. Cooper Z, Doll HA, Hawker DM, et al. Testing a new cognitive behavioural treatment for obesity: a randomized controlled trial with three-year follow-up. Behav Res Ther. 2010;48:706–713.
18. Mason AE, Jhaveri K, Cohn M, Brewer JA. Testing a mobile mindful eating intervention targeting craving-related eating: feasibility and proof of concept. J Behav Med. 2018;41:160–173.
19. Forman EM, Butryn ML, Manasse SM, et al. Acceptance-based versus standard behavioral treatment for obesity: Results from the mind your health randomized controlled trial. Obesity (Silver Spring). 2016;24:2050–2056.
20. Hsu RK, McCulloch CE, Dudley RA, Lo LJ, Hsu CY. Temporal changes in incidence of dialysis-requiring AKI. J Am Soc Nephrol. 2013;24:37–42.
21. Susantitaphong P, Cruz DN, Cerda J, et al. World incidence of AKI: a meta-analysis. Clin J Am Soc Nephrol. 2013;8:1482–1493.